Koele, S.E.* ; Heinrich, N.* ; De Jager, V.R.* ; Dreisbach, J.* ; Phillips, P.P.J.* ; Gross-Demel, P.* ; Dawson, R.* ; Narunsky, K.* ; Wildner, L.M.* ; McHugh, T.D.* ; Te Brake, L.H.M.* ; Diacon, A.H.* ; Aarnoutse, R.E.* ; Hoelscher, M. ; Svensson, E.M.*
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.
J. Antimicrob. Chemother. 80, 1315-1323 (2025)
INTRODUCTION: BTZ-043 is a first-in-class benzothiazinone for the treatment of TB with demonstrated early bactericidal activity. BTZ-043 is metabolized into two major metabolites: M1 and M2. The aim of this study was to characterize the pharmacokinetics (PK) and early exposure-response (pharmacokinetic/pharmacodynamic, PK/PD) relationship for BTZ-043. METHODS: A population PK/PD model for BTZ-043 and its metabolites was developed using data from a sequential Phase 1b/2a, randomized, controlled clinical trial in participants with pulmonary TB. BTZ-043 was administered in daily doses ranging from 250 to 1750 mg over 14 days. The decrease in bacterial load was determined by culture of sputum samples to quantify cfu on solid medium, and time to positivity in liquid medium. RESULTS: In total, 77 participants received the experimental treatment. PK were best described by two-compartment disposition models for BTZ-043 and M2, and a one-compartment disposition model for M1. When given without food, the bioavailability was 54% (95% CI: 43%-65%) lower than with food. The decrease in bacterial load was described by a bilinear model with estimated node at 48 h. Participants in the highest dose group in Stage 2 (1000 mg) had a 2-fold faster decrease in mycobacterial load during the initial 2 days compared with participants in the lowest dose group (250 mg), driven by an Emax relationship to the BTZ-043total exposure (BTZ-043 + M2). CONCLUSIONS: We characterized the population PK/PD of BTZ-043 in trial participants with pulmonary TB. An exposure-response relationship was only apparent for the first 2 days on treatment, indicating the need for further dose-finding studies.
Altmetric
Additional Metrics?
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Corresponding Author
Keywords
Early Bactericidal Activity; Mycobacterium-tuberculosis; Model
Keywords plus
ISSN (print) / ISBN
0305-7453
e-ISSN
1460-2091
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 80,
Issue: 5,
Pages: 1315-1323
Article Number: ,
Supplement: ,
Series
Publisher
Oxford University Press
Publishing Place
Great Clarendon St, Oxford Ox2 6dp, England
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
Institute(s)
Research Unit Global Health (UGH)
Grants
Swiss State Secretariat for Education, Research, and Innovation
Bavarian Ministry for Science and the Arts
German Center for Infection Research
Dutch Research Council
Copyright